Skip to main content

and
  1. No Access

    Article

    Unconventional T Cells Influence Clinical Outcome After Allogeneic Hematopoietic Cell Transplantation

    We evaluated the impact of early recovery of mucosal-associated invariant T cells (MAIT) and gamma-delta (γδ) T cells, especially Vδ2+ T cells, on the clinical outcomes of 76 patients who underwent allogeneic hem...

    Lama Siblany, Nicolas Stocker, Laure Ricard in Journal of Clinical Immunology (2024)

  2. No Access

    Article

    Microbiota dysbiosis after high-dose melphalan and autologous hematopoietic cell transplantation in multiple myeloma

    Florent Malard, Giorgia Battipaglia, Béatrice Gaugler in Bone Marrow Transplantation (2023)

  3. No Access

    Article

    Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation

    Post-transplant cyclophosphamide (PT-Cy) is effective for graft-versus-host disease (GVHD) prophylaxis, but it may cause dose-dependent toxicities, particularly in frail patients. Therefore, we compared the ou...

    Rémy Duléry, Florent Malard, Eolia Brissot, Anne Banet in Bone Marrow Transplantation (2023)

  4. No Access

    Article

    Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies

    Although post-transplant cyclophosphamide (PT-Cy) is effective for graft-versus-host disease (GVHD) prophylaxis, it is associated with toxicities, which might be dose-dependent. We compared the outcomes with P...

    Rémy Duléry, Claire Goudet, Daniele Mannina in Bone Marrow Transplantation (2023)

  5. Article

    Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases

    Armelle Otiniano, Zoe van de Wyngaert, Eolia Brissot in Bone Marrow Transplantation (2023)

  6. Article

    Open Access

    Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)

    Despite the implementation of new therapeutic agents, management of relapsed multiple myeloma (MM) remains a challenge. Salvage autologous hematopoietic cell transplant (AHCT) remains a valid therapeutic optio...

    Zoe van de Wyngaert, Florent Malard, Cyrille Hulin in Clinical Hematology International (2023)

  7. No Access

    Article

    Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation

    For acute lymphoblastic leukemia (ALL) patients, total body irradiation (TBI)- based conditioning regimens are the first choice specially in young population. However, several studies have shown an equivalence...

    Anne Banet, Ali Bazarbachi, Myriam Labopin, Nicolas Stocker in Bone Marrow Transplantation (2023)

  8. No Access

    Article

    Photobiomodulation: a promising innovative approach for preventing oral mucositis in patients undergoing hematopoietic stem cell transplantation

    This single-center retrospective study aims to assess the feasibility, safety, and tolerability of CareMin650, a new photobiomodulation device, for both preventing oral mucositis (OM) and reducing its severity...

    Nicolas Stocker, Virginie Baltes, Solal Bellaiche in Supportive Care in Cancer (2022)

  9. Article

    Open Access

    Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

    This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) correlated with anti-Spike (S) I...

    Florent Malard, Béatrice Gaugler, Joel Gozlan, Lucie Bouquet in Blood Cancer Journal (2021)

  10. No Access

    Article

    Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma

    Mobilization of peripheral blood stem cells (PBSC) can be performed using plerixafor, which is expensive, or high-dose cyclophosphamide (HDCy). We hypothesized that the overall cost of mobilization with plerix...

    Zoé Van de Wyngaert, Virginie Nerich, Guillemette Fouquet in Bone Marrow Transplantation (2020)

  11. Article

    COVID-19 outcomes in patients with hematologic disease

    Florent Malard, Alexis Genthon, Eolia Brissot in Bone Marrow Transplantation (2020)